What changed recently
Newly published and updated guidelines across every system, newest first. Each entry links to the official source.
25 older updates are outside this window. Show all time
- CardiovascularEU2025-08-292021 → 2025Mitral regurgitation
The 2025 guideline replaces the 2021 edition and moves mitral intervention earlier: repair surgery becomes a Class I option in selected asymptomatic primary mitral regurgitation, and transcatheter edge-to-edge repair is upgraded to Class I in symptomatic severe ventricular secondary regurgitation with reduced ejection fraction, with new recommendations added for atrial secondary regurgitation.
source ↗curation confidence 90% - CardiovascularEU2025-08-292021 → 2025Aortic stenosis
Updating the 2021 ESC/EACTS guideline, the 2025 version lowers the age cut-off favouring transcatheter aortic valve implantation in tricuspid aortic stenosis from 75 to 70 years, tightens the echocardiographic criteria for grading stenosis severity, and lowers thresholds for intervening earlier.
source ↗curation confidence 90% - CardiovascularEU2025-06-152019 → 2025 Focused UpdateDyslipidemia
2025 focused update of the 2019 ESC/EAS guideline, incorporating newer lipid-lowering trial evidence while retaining risk-based LDL-C goals.
- CardiovascularUS2025-06-152017 → 2025Hypertension
First full US revision since 2017: adopts the PREVENT equations for risk estimation (replacing the Pooled Cohort Equations) and reaffirms a <130/80 mm Hg treatment goal.
- CardiovascularUS2025-02-272013 STEMI / 2014 NSTEMI guidelines → 2025Post-MI care
The 2025 guideline consolidates the 2013 STEMI, 2014 NSTEMI and 2015 primary-PCI focused update into one document covering the whole ACS spectrum, and refreshes post-infarction antithrombotic and revascularisation guidance, including intracoronary imaging to guide PCI and revised anticoagulant choices.
- CardiovascularUS2025-02-272013 STEMI / 2014 NSTEMI guidelines → 2025Acute coronary syndrome
The 2025 guideline merges the separate 2013 STEMI and 2014 NSTEMI documents (plus the 2015 primary-PCI focused update) into a single guideline spanning unstable angina, NSTE-ACS and STEMI. New positions include a recommendation to use intracoronary imaging to guide PCI, a weak (Class 2b) option for bivalirudin in NSTE-ACS to limit bleeding, and advice against fondaparinux as the sole anticoagulant during PCI.